339 related articles for article (PubMed ID: 18193087)
21. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
22. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
Danhauser-Riedl S; Warmuth M; Druker BJ; Emmerich B; Hallek M
Cancer Res; 1996 Aug; 56(15):3589-96. PubMed ID: 8758931
[TBL] [Abstract][Full Text] [Related]
23. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line.
Laneuville P; Heisterkamp N; Groffen J
Oncogene; 1991 Feb; 6(2):275-82. PubMed ID: 1705688
[TBL] [Abstract][Full Text] [Related]
24. Modeling Philadelphia chromosome positive leukemias.
Wong S; Witte ON
Oncogene; 2001 Sep; 20(40):5644-59. PubMed ID: 11607816
[TBL] [Abstract][Full Text] [Related]
25. Influence of BCR/ABL fusion proteins on the course of Ph leukemias.
Telegeev GD; Dubrovska AN; Dybkov MV; Maliuta SS
Acta Biochim Pol; 2004; 51(3):845-9. PubMed ID: 15448745
[TBL] [Abstract][Full Text] [Related]
26. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
[TBL] [Abstract][Full Text] [Related]
27. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.
Stoklosa T; Poplawski T; Koptyra M; Nieborowska-Skorska M; Basak G; Slupianek A; Rayevskaya M; Seferynska I; Herrera L; Blasiak J; Skorski T
Cancer Res; 2008 Apr; 68(8):2576-80. PubMed ID: 18413724
[TBL] [Abstract][Full Text] [Related]
28. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Daley GQ; Van Etten RA; Baltimore D
Science; 1990 Feb; 247(4944):824-30. PubMed ID: 2406902
[TBL] [Abstract][Full Text] [Related]
29. A novel 53 kDa protein complexed with P210bcr-abl in human chronic myelogenous leukemia cells.
Li WJ; Kloetzer WS; Arlinghaus RB
Oncogene; 1988 Jun; 2(6):559-66. PubMed ID: 3133627
[TBL] [Abstract][Full Text] [Related]
30. Bcr/Abl P190 interaction with Spa-1, a GTPase activating protein for the small GTPase Rap1.
Yi SJ; Lee HT; Groffen J; Heisterkamp N
Int J Mol Med; 2008 Oct; 22(4):453-8. PubMed ID: 18813851
[TBL] [Abstract][Full Text] [Related]
31. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.
Le Y; Xu L; Lu J; Fang J; Nardi V; Chai L; Silberstein LE
Am J Hematol; 2009 May; 84(5):273-8. PubMed ID: 19358301
[TBL] [Abstract][Full Text] [Related]
32. Detection of P210bcr-abl in mature granulocytes from Ph1-positive chronic myelogenous leukemia patients by an immunoblotting method.
Kuwao F; Takahashi I
Leukemia; 1993 Aug; 7(8):1168-73. PubMed ID: 8350617
[TBL] [Abstract][Full Text] [Related]
33. Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice.
Honda H; Fujii T; Takatoku M; Mano H; Witte ON; Yazaki Y; Hirai H
Blood; 1995 May; 85(10):2853-61. PubMed ID: 7537982
[TBL] [Abstract][Full Text] [Related]
34. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl.
Laneuville P; Sun G; Timm M; Vekemans M
Blood; 1992 Oct; 80(7):1788-97. PubMed ID: 1327283
[TBL] [Abstract][Full Text] [Related]
35. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.
Estrov Z; Talpaz M; Kantarjian HM; Zipf TF; McClain KL; Kurzrock R
Cancer Res; 1993 Jul; 53(14):3289-93. PubMed ID: 8324740
[TBL] [Abstract][Full Text] [Related]
37. The biology of chronic myelogenous leukemia:mouse models and cell adhesion.
Wertheim JA; Miller JP; Xu L; He Y; Pear WS
Oncogene; 2002 Dec; 21(56):8612-28. PubMed ID: 12476308
[TBL] [Abstract][Full Text] [Related]
38. Phosphotyrosine phosphatase activity prevents the detection of P210bcr/abl protein in mature cells in chronic myelogenous leukemia even by an immunoblotting technique.
Shibata K; Nishimura J; Takahira H; Nawata H
Leukemia; 1989 Sep; 3(9):615-9. PubMed ID: 2474729
[TBL] [Abstract][Full Text] [Related]
39. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells.
Hallek M; Danhauser-Riedl S; Herbst R; Warmuth M; Winkler A; Kolb HJ; Druker B; Griffin JD; Emmerich B; Ullrich A
Br J Haematol; 1996 Jul; 94(1):5-16. PubMed ID: 8757502
[TBL] [Abstract][Full Text] [Related]
40. High incidence of proviral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell leukemia.
Bijl J; Sauvageau M; Thompson A; Sauvageau G
Genes Dev; 2005 Jan; 19(2):224-33. PubMed ID: 15655112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
